Evidence map›Paper›PMID 36361667›Full record

ArticleInternational journal of molecular sciences2022

A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation.

Martina Capozza, Rachele Stefania, Valentina Dinatale, Valeria Bitonto, Laura Conti, Cristina Grange, Renata Skovronova, Enzo Terreno

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Lessons learned in application driven imaging agent design for image-guided surgery.European journal of nuclear medicine and molecular imaging · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Martina CapozzaMolecular & Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.ORCID 0000-0001-9125-8004
Rachele StefaniaMolecular & Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.
Valentina DinataleMolecular & Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.
Valeria BitontoMolecular & Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.ORCID 0000-0003-2138-0658
Laura ContiMolecular Biotechnology Center, Department of Medical Science, University of Torino, 10126 Torino, Italy.ORCID 0000-0003-1780-098X
Cristina GrangeMolecular Biotechnology Center, Department of Medical Science, University of Torino, 10126 Torino, Italy.ORCID 0000-0002-6960-5476
Renata SkovronovaMolecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.ORCID 0000-0003-0217-5309
Enzo TerrenoMolecular & Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.ORCID 0000-0003-3800-566X
University of Turin · IT

Funding

Italian Association for Cancer Research 20124
6 · The paper itself

Abstract

A total of 20% to 50% of prostate cancer (PCa) patients leave the surgery room with positive tumour margins. The intraoperative combination of fluorescence guided surgery (FGS) and photodynamic therapy (PDT) may be very helpful for improving tumour margin delineation and cancer therapy. PSMA is a transmembrane protein overexpressed in 90−100% of PCa cells. The goal of this work is the development of a PSMA-targeted Near InfraRed Fluorescent probe to offer the surgeon a valuable intraoperative tool for allowing a complete tumour removal, implemented with the possibility of using PDT to kill the eventual not resected cancer cells. PSMA-617 binding motif was conjugated to IRDye700DX-NHS and the conjugation did not affect the photophysical characteristics of the fluorophore. The affinity of IRDye700DX-PSMA-617 towards PCa cells followed the order of their PSMA expression, i.e., PC3-PIP > LNCaP > PC3, PC3-FLU. NIRF imaging showed a significant PC3-PIP tumour uptake after the injection of 1 or 5 nmol with a maximum tumour-to-muscle ratio (ca. 60) observed for both doses 24 h post-injection. Importantly, urine, healthy prostate, and the bladder were not fluorescent at 24 h post-injection. Flow cytometry and confocal images highlighted a co-localization of PSMA+ cells with IRDye700DX-PSMA uptake. Very interestingly, ex vivo analysis on a tumour specimen highlighted a significant PSMA expression by tumour-associated macrophages, likely attributable to extracellular vesicles secreted by the PSMA(+) tumour cells. FGS proved that IRDye700DX-PSMA was able to easily delineate tumour margins. PDT experiments showed a concentration-dependent decrease in cell viability (from 75% at 10 nM to 12% at 500 nM), whereas controls did not show any cytotoxicity. PC3-PIP tumour-bearing mice subjected to photodynamic therapy showed a delayed tumour growth. In conclusion, a novel PSMA-targeted NIRF dye with dual imaging-PDT capabilities was synthesized and displayed superior specificity compared to other small PSMA targeted molecules.

Indexed as

PhotochemotherapyProstatic NeoplasmsSurgery, Computer-AssistedAnimalsAntigens, SurfaceCell Line, TumorFluorescent DyesHumansMaleMiceAntigens, SurfaceFluorescent Dyesextracellular vesiclesimage-guided surgeryNIRF imagingphotodynamic therapyprostate cancerPSMA

Identifiers

PMID36361667
PMCPMC9657290
OpenAlexW4308165677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.